scholarly journals Intake of specific carotenoids and the risk of epithelial ovarian cancer

2007 ◽  
Vol 98 (1) ◽  
pp. 187-193 ◽  
Author(s):  
Min Zhang ◽  
C. D'Arcy J. Holman ◽  
Colin W. Binns

There has been considerable interest in the role of carotenoids in the chemoprevention of cancer. However, few studies have examined the association between intake of specific carotenoids and the risk of epithelial ovarian cancer and the results for carotenoids have been inconclusive. To investigate whether the intake of α-carotene, β-carotene, β-cryptoxanthin, lutein and zeaxanthin, and lycopene is inversely associated with ovarian cancer risk, a case–control study was conducted in China during 1999–2000. The cases were 254 patients with histologically confirmed epithelial ovarian cancer and 652 age-matched controls were randomly recruited during the same period. Habitual dietary intake and lifestyle were collected by face-to-face interview using a validated and reliable FFQ. The US Department of Agriculture nutrient composition database was used to calculate the intake of specific carotenoids. Unconditional logistic regression analyses were used to estimate OR and 95 % CI, accounting for age, locality, education, BMI, smoking, tea drinking, parity, oral contraceptive use, hormone replacement therapy, menopausal status, family history of ovarian cancer, physical activity and energy intake. Compared with the highest v. the lowest quartile of intake, the adjusted OR were 0·39 (95 % CI 0·23, 0·66) for α-carotene, 0·51 (95 % CI 0·31, 0·84) for β-carotene, 0·51 (95 % CI 0·31, 0·83) for β-cryptoxanthin, 0·45 (0·27, 0·76) for lutein and zeaxanthin, and 0·33 (95 % CI 0·20, 0·56) for total carotenoids, with statistically significant tests for trend. It is concluded that a higher intake of carotenoids can reduce the risk of epithelial ovarian cancer.

2003 ◽  
Vol 9 (2) ◽  
pp. 61-68 ◽  
Author(s):  
Tomas Riman

Recently it was estimated that about one-third of postmenopausal British women aged 50-64 years currently uses hormone replacement therapy (HRT) for treatment of climacteric symptoms and for other medical reasons. To reduce an excess risk of endometrial cancer induced by oestrogens, modern HRT regimens contain either sequential or continuous progestogens. The protective effect of parity and oral contraceptive use observed in the majority of epidemiological studies on epithelial ovarian cancer (EOC) suggest that hormonal factors are likely to operate in ovarian carcinogenesis. However, the studies where HRT was examined in relation to the risk of EOC have reported conflicting results. The objective of this epidemiological review is to evaluate the risk of EOC in relation to the use of HRT, with particular focus on the few studies where oestrogens and progestogens in HRT were assessed separately. Further, the findings regarding HRT and EOC risk will be discussed in the context of available aetiological hypotheses. Finally, any clinical implications are commented upon.


Epidemiology ◽  
2008 ◽  
Vol 19 (2) ◽  
pp. 237-243 ◽  
Author(s):  
Galina Lurie ◽  
Lynne R. Wilkens ◽  
Pamela J. Thompson ◽  
Katharine E. McDuffie ◽  
Michael E. Carney ◽  
...  

2016 ◽  
Vol 116 (2) ◽  
pp. 265-269 ◽  
Author(s):  
Linda S Cook ◽  
Claire R Pestak ◽  
Andy CY Leung ◽  
Helen Steed ◽  
Jill Nation ◽  
...  

2005 ◽  
Vol 162 (1) ◽  
pp. 66-72 ◽  
Author(s):  
Julia B. Greer ◽  
Francesmary Modugno ◽  
Glenn O. Allen ◽  
Roberta B. Ness

Sign in / Sign up

Export Citation Format

Share Document